Skip to main content
DongKook Life Science Co., Ltd. logo

DongKook Life Science Co., Ltd. — Investor Relations & Filings

Ticker · 303810 ISIN · KR7303810006 KO Manufacturing
Open in API
Filings indexed 69 across all filing types
Latest filing 2024-12-30 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 303810

About DongKook Life Science Co., Ltd.

http://www.dkls.co.kr/eng/

DongKook Life Science Co., Ltd. is a specialized pharmaceutical company focused on diagnostic medicine and medical devices. The company develops, manufactures, and supplies a range of products with a core specialization in contrast media for medical imaging modalities such as X-ray and magnetic resonance imaging (MRI). In addition to its diagnostic pharmaceuticals, the company is involved in developing AI-powered medical technology. With a strong emphasis on research and development, DongKook Life Science focuses on technical innovation and the creation of new products, having successfully localized key diagnostic medicines for the market. The company serves a global customer base across numerous countries.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Correction Report' (정정신고서) for a Securities Registration Statement (증권신고서) filed by Dongkook Life Science. It details changes to the public offering schedule, including dates for demand forecasting, subscription, and payment. This is a formal regulatory filing related to a capital raising activity (IPO/share issuance) and does not fit into the 'Report Publication Announcement' category because it contains substantive updates to the offering terms rather than just a notification of a report's availability.
2024-12-30 Korean
증권신고서(지분증권)
Capital/Financing Update Classification · 100% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details a public offering of shares (2,000,000 shares) by Dongkook Life Science Co., Ltd. The document includes comprehensive information regarding the offering, investment risks, and business operations, which is characteristic of a formal regulatory filing for a capital raise. Since it is a formal registration statement for a public offering of equity, it falls under the 'Capital/Financing Update' category.
2024-12-16 Korean
감사보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Dongkook Life Science Co., Ltd. for the fiscal year ending December 31, 2023. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial report, not an announcement or a summary, and therefore fits the definition of an Audit Report/Information (AR). FY 2023
2024-03-22 Korean
감사보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Dongkook Life Science Co., Ltd. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. It covers the fiscal year ending December 31, 2022. While it contains financial statements, it is explicitly titled as an audit report and includes the auditor's opinion, which aligns with the 'Audit Report / Information' category. FY 2022
2023-03-31 Korean
[기재정정]감사보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Dongkook Life Science Co., Ltd. It includes the independent auditor's report, financial statements (balance sheet, income statement, etc.), and detailed notes. It is not an Annual Report (10-K) as it focuses specifically on the audit results and financial statements rather than the broader company activity report. It is not an RPA because it is a full, comprehensive report, not an announcement of one. FY 2022
2023-03-31 Korean
감사보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Dongkook Life Science Co., Ltd. for the fiscal year 2021. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. It is a comprehensive financial document prepared in accordance with K-IFRS, not an announcement or a summary. Therefore, it is classified as an Audit Report. FY 2021
2022-04-06 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.